BACKGROUND: There are no effective indicators of graft dysfunction in islet transplantation. This study evaluated the role of the Continuous Glucose Monitoring System (CGMS) as an early indicator of graft dysfunction in islet transplant recipients. METHODS: In 5 islet allograft recipients, we retrospectively determined the date of graft dysfunction: 3 fasting blood glucose levels >7.8 mmol/L (140 mg/dL) and/or 3 postprandial blood glucose levels >10 mmol/L (180 mg/dL) in 1 week. We then determined 2 time points in respect to graft dysfunction, 5 to 9 months before (time point A) and 2 to 3 months before (time point B). For these 2 time points, we assessed the following: HbA1c, C-peptide (CP), C-peptide glucose ratio (CPGR), 90-minute glucose from mixed meal tolerance test, and percentage of capillary blood glucose levels >7.8 mmol/L (%CBG >7.8) in a 15-day interval (1 week before and after CGMS placement). From the CGMS recordings, we calculated the glucose variability and the percentage of time spent in hyperglycemia >7.8 mmol/L (%HGT >7.8) and >10 mmol/L (%HGT >10). RESULTS: No difference was found between time points A and B for the following parameters: HbA1c, CP, CPGR, 90-minute glucose, %CBG >7.8, and %HGT >10. We observed a statistically significant increase from time point A to time point B in glucose variability (1.1 +/- 0.5 mmol/L to 1.6 +/- 0.6 mmol/L; P = .004), and in the %HGT >7.8 (11 +/- 12% to 22 +/- 18%; P = .036). CONCLUSION: Glucose variability and %HGT >7.8 determined using CGMS are useful as early indicators of graft dysfunction in islet transplant recipients. Further studies with larger sample sizes will help validate these observations.
BACKGROUND: There are no effective indicators of graft dysfunction in islet transplantation. This study evaluated the role of the Continuous Glucose Monitoring System (CGMS) as an early indicator of graft dysfunction in islet transplant recipients. METHODS: In 5 islet allograft recipients, we retrospectively determined the date of graft dysfunction: 3 fasting blood glucose levels >7.8 mmol/L (140 mg/dL) and/or 3 postprandial blood glucose levels >10 mmol/L (180 mg/dL) in 1 week. We then determined 2 time points in respect to graft dysfunction, 5 to 9 months before (time point A) and 2 to 3 months before (time point B). For these 2 time points, we assessed the following: HbA1c, C-peptide (CP), C-peptide glucose ratio (CPGR), 90-minute glucose from mixed meal tolerance test, and percentage of capillary blood glucose levels >7.8 mmol/L (%CBG >7.8) in a 15-day interval (1 week before and after CGMS placement). From the CGMS recordings, we calculated the glucose variability and the percentage of time spent in hyperglycemia >7.8 mmol/L (%HGT >7.8) and >10 mmol/L (%HGT >10). RESULTS: No difference was found between time points A and B for the following parameters: HbA1c, CP, CPGR, 90-minute glucose, %CBG >7.8, and %HGT >10. We observed a statistically significant increase from time point A to time point B in glucose variability (1.1 +/- 0.5 mmol/L to 1.6 +/- 0.6 mmol/L; P = .004), and in the %HGT >7.8 (11 +/- 12% to 22 +/- 18%; P = .036). CONCLUSION:Glucose variability and %HGT >7.8 determined using CGMS are useful as early indicators of graft dysfunction in islet transplant recipients. Further studies with larger sample sizes will help validate these observations.
Authors: Breay W Paty; Peter A Senior; Jonathan R T Lakey; A M James Shapiro; Edmond A Ryan Journal: Diabetes Technol Ther Date: 2006-04 Impact factor: 6.118
Authors: Tatiana Froud; Camillo Ricordi; David A Baidal; Muhammad M Hafiz; Gaston Ponte; Pablo Cure; Antonello Pileggi; Raffaella Poggioli; Hirohito Ichii; Aisha Khan; Jacqueline V Ferreira; Alberto Pugliese; Violet V Esquenazi; Norma S Kenyon; Rodolfo Alejandro Journal: Am J Transplant Date: 2005-08 Impact factor: 8.086
Authors: Milene C Geiger; Jacqueline V Ferreira; Muhammad M Hafiz; Tatiana Froud; David A Baidal; Luigi F Meneghini; Camillo Ricordi; Rodolfo Alejandro Journal: Cell Transplant Date: 2005 Impact factor: 4.064
Authors: Laurence Kessler; Raphael Passemard; Jose Oberholzer; Pierre Yves Benhamou; Pascal Bucher; Christian Toso; Pierre Meyer; Alfred Penfornis; Lionel Badet; Philippe Wolf; Cyrille Colin; Philippe Morel; Michel Pinget Journal: Diabetes Care Date: 2002-12 Impact factor: 19.112
Authors: A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: Edmond A Ryan; Breay W Paty; Peter A Senior; Jonathan R T Lakey; David Bigam; A M James Shapiro Journal: Diabetes Care Date: 2005-02 Impact factor: 19.112
Authors: R Alejandro; R Lehmann; C Ricordi; N S Kenyon; M C Angelico; G Burke; V Esquenazi; J Nery; A E Betancourt; S S Kong; J Miller; D H Mintz Journal: Diabetes Date: 1997-12 Impact factor: 9.461
Authors: Edmond A Ryan; Breay W Paty; Peter A Senior; David Bigam; Eman Alfadhli; Norman M Kneteman; Jonathan R T Lakey; A M James Shapiro Journal: Diabetes Date: 2005-07 Impact factor: 9.461